seRNAs represent a pro-drug platform technology that can easily be adapted to numerous therapeutic areas by utilizing the transcriptome for selective cell targeting and Fusogenic Liposomes for organ specific pre-targeting.
seRNAs can be designed from modular building blocks, creating a platform technology that can be quickly adapted and applied to numerous indications.
seRNAs have a unique mode of action: They enter any cell BUT will only be activated in tumor cells by tumor cell specific RNAs, forming dsRNA with the antisense part of seRNA. seRNA activation results in cell-specific expression of effector molecules in tumor cells only.
To deliver seRNAs we are utilizing Fusogenic liposomes (FL)
which allow and enable:
seRNAs have a modular set-up and combine RNAi and mRNA